Intoplicine - Sanofi Oncology
Alternative Names: NSC-645008; RP 60475Latest Information Update: 24 Oct 2021
Price :
$50 *
At a glance
- Originator ILEX Oncology Inc
- Class Antineoplastics; Indoles; Pyridines; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Cancer metastases; Solid tumours
Most Recent Events
- 27 Aug 2018 Genzyme completes a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Canada (IV-infusion) (NCT00003713)
- 17 Jun 2002 Discontinued - Phase-I for Cancer metastases in USA (IV-infusion)
- 17 Jun 2002 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada (IV-infusion)